Long Noncoding RNA MALAT-1 is a New Potential Therapeutic Target for Castration Resistant Prostate Cancer
2013; Lippincott Williams & Wilkins; Volume: 190; Issue: 6 Linguagem: Inglês
10.1016/j.juro.2013.07.001
ISSN1527-3792
AutoresShancheng Ren, Yawei Liu, Weidong Xu, Yi Sun, Ji Lu, Fubo Wang, Min Wei, Jian Shen, Jianguo Hou, Xu Gao, Chuanliang Xu, Jiaoti Huang, Yi Zhao, Yinghao Sun,
Tópico(s)Prostate Cancer Treatment and Research
ResumoNo AccessJournal of UrologyInvestigative Urology1 Dec 2013Long Noncoding RNA MALAT-1 is a New Potential Therapeutic Target for Castration Resistant Prostate Cancer Shancheng Ren, Yawei Liu, Weidong Xu, Yi Sun, Ji Lu, Fubo Wang, Min Wei, Jian Shen, Jianguo Hou, Xu Gao, Chuanliang Xu, Jiaoti Huang, Yi Zhao, and Yinghao Sun Shancheng RenShancheng Ren Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Yawei LiuYawei Liu Health Division of Guard Bureau, General Staff Department of Chinese People's Liberation Army, Beijing, People's Republic of China , Weidong XuWeidong Xu Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Yi SunYi Sun Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Ji LuJi Lu Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Fubo WangFubo Wang Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Min WeiMin Wei Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Jian ShenJian Shen Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Jianguo HouJianguo Hou Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Xu GaoXu Gao Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Chuanliang XuChuanliang Xu Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China , Jiaoti HuangJiaoti Huang Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California , Yi ZhaoYi Zhao Bioinformatics Research Group, Key Laboratory of Intelligent Information Processing, Advanced Computer Research Center, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, People's Republic of China , and Yinghao SunYinghao Sun Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China View All Author Informationhttps://doi.org/10.1016/j.juro.2013.07.001AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: To understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 silencing on castration resistant prostate cancer cells in vitro and in vivo. Materials and Methods: Quantitative reverse transcriptase-polymerase chain reaction was used to detect MALAT-1 expression in prostate cancer tissues and cell lines. siRNA against MALAT-1 was designed and the silencing effect was examined by quantitative reverse transcriptase-polymerase chain reaction. The biological effects of MALAT-1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays as well as cell migration by in vitro scratch assay, cell invasion by Transwell® invasion assay and cell cycle by flow cytometry. We further investigated the effect of therapeutic siRNA targeting MALAT-1 on castration resistant prostate cancer in vivo. Results: MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. Importantly, intratumor delivery of therapeutic siRNA targeting MALAT-1 elicited delayed tumor growth and reduced metastasis of prostate cancer xenografts in castrated male nude mice, followed by the concomitant prolongation of survival of tumor bearing mice. Conclusions: MALAT-1 may be needed to maintain prostate tumorigenicity and it is involved in prostate cancer progression. Thus, MALAT-1 may serve as a potential therapeutic target for castration resistant prostate cancer. References 1 : Cancer statistics, 2013. CA Cancer J Clin2013; 63: 11. Google Scholar 2 : Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg Oncol2009; 18: 268. Google Scholar 3 : Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am2001; 28: 555. Google Scholar 4 : Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol2005; 23: 8253. Google Scholar 5 : Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer. BJU Int, suppl2012; 110: 14. Google Scholar 6 : Long non-coding RNAs: insights into functions. Nat Rev Genet2009; 10: 155. Google Scholar 7 : The functional role of long non-coding RNA in human carcinomas. Mol Cancer2011; 10: 38. Google Scholar 8 : The transcriptional landscape of the mammalian genome. Science2005; 309: 1559. Google Scholar 9 : Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. Science2005; 308: 1149. Google Scholar 10 : Noncoding RNA in development. Mamm Genome2008; 19: 454. Google Scholar 11 : Long non-coding RNAs and enhancers. Curr Opin Genet Dev2011; 21: 194. Google Scholar 12 : Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res2008; 18: 1433. Google Scholar 13 : Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell2007; 129: 1311. Google Scholar 14 : Cloning of the mRNA of overexpression in colon carcinoma-1: a sequence overexpressed in a subset of colon carcinomas. Cancer Genet Cytogenet2002; 133: 55. Google Scholar 15 : Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol2006; 25: 135. Google Scholar 16 : Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell2007; 12: 215. Google Scholar 17 : A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene2007; 26: 851. Google Scholar 18 : DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res1999; 59: 5975. Google Scholar 19 : MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene2003; 22: 8031. Google Scholar 20 : Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol2012; 29: 1810. Google Scholar 21 : MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett2010; 584: 4575. Google Scholar 22 : Phenotypic characterization of endometrial stromal sarcoma of the uterus. Cancer Sci2006; 97: 106. Google Scholar 23 : MALAT-1: a long non-coding RNA and its important 3′ end functional motif in colorectal cancer metastasis. Int J Oncol2011; 39: 169. Google Scholar 24 : In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protocols2007; 2: 329. Google Scholar 25 : Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene2007; 26: 3006. Google Scholar 26 : Metastasis associated lung adenocarcinoma transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with trophoblast-like cell invasion in vitro. Mol Hum Reprod2009; 15: 725. Google Scholar 27 : Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature2010; 464: 1071. Google Scholar 28 : The emergence of lncRNAs in cancer biology. Cancer Discov2011; 1: 391. Google Scholar 29 : MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl)2013; 91: 791. Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAtala A (2020) Re: Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-κB ActivationJournal of Urology, VOL. 204, NO. 3, (622-622), Online publication date: 1-Sep-2020.Atala A (2016) Re: Integrative Analyses Reveal a Long Noncoding RNA-Mediated Sponge Regulatory Network in Prostate CancerJournal of Urology, VOL. 197, NO. 3 Part 1, (701-701), Online publication date: 1-Mar-2017.Atala A (2017) Re: Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate CancerJournal of Urology, VOL. 198, NO. 1, (103-104), Online publication date: 1-Jul-2017.Atala A (2014) Re: lncRNA-Dependent Mechanisms of Androgen-Receptor-Regulated Gene Activation ProgramsJournal of Urology, VOL. 191, NO. 5, (1470-1471), Online publication date: 1-May-2014.Atala A (2014) Re: The Long Noncoding RNA SChLAP1 Promotes Aggressive Prostate Cancer and Antagonizes the SWI/SNF ComplexJournal of Urology, VOL. 192, NO. 2, (613-615), Online publication date: 1-Aug-2014.Atala A (2014) Re: Preclinical Efficacy of Growth Hormone-Releasing Hormone Antagonists for Androgen-Dependent and Castration-Resistant Human Prostate CancerJournal of Urology, VOL. 192, NO. 3, (998-999), Online publication date: 1-Sep-2014.Andersson K (2013) This Month in Investigative UrologyJournal of Urology, VOL. 190, NO. 6, (1968-1969), Online publication date: 1-Dec-2013. Volume 190Issue 6December 2013Page: 2278-2287Supplementary Materials Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.KeywordsRNAhumansmall interferingantiandrogensprostateprostatic neoplasmsMALAT1 long non-coding RNAAcknowledgmentsBioneer China provided siRNA.MetricsAuthor Information Shancheng Ren Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China Equal study contribution. More articles by this author Yawei Liu Health Division of Guard Bureau, General Staff Department of Chinese People's Liberation Army, Beijing, People's Republic of China Equal study contribution. More articles by this author Weidong Xu Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China Equal study contribution. More articles by this author Yi Sun Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Ji Lu Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Fubo Wang Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Min Wei Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Jian Shen Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Jianguo Hou Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Xu Gao Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Chuanliang Xu Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Jiaoti Huang Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California More articles by this author Yi Zhao Bioinformatics Research Group, Key Laboratory of Intelligent Information Processing, Advanced Computer Research Center, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, People's Republic of China More articles by this author Yinghao Sun Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)